Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing ...
Nov 26, 2025 · Teva Pharmaceuticals announced data from the ongoing real-world phase 4 study, coined IMPACT-TD Registry, evaluating the efficacy of deutetrabenazine (Austedo) tablets and its …
Clinical & Real-World Studies | AUSTEDO XR® (deutetrabenazine) …
See Prescribing Information, including Boxed Warning. Review results from the pivotal studies for AUSTEDO.
Teva Pharmaceuticals Reports Positive Real-World Data on AUSTEDO …
Nov 7, 2025 · The data presented at a significant neuroscience congress demonstrate the effectiveness of AUSTEDO and AUSTEDO XR in reducing the severity of involuntary movements and enhancing …
Clinical Studies Results | AUSTEDO (deutetrabenazine)
See Important Safety Information, including Boxed Warning. Learn about the results of the clinical studies done for AUSTEDO XR® (deutetrabenazine) tablets.
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
4 days ago · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.
Real-World Data Show AUSTEDO XR Delivers High Patient Satisfaction …
Teva Pharmaceuticals has announced compelling real-world evidence demonstrating the effectiveness of AUSTEDO XR (deutetrabenazine) extended-release tablets in treating tardive dyskinesia (TD), …
Teva’s New Real-World Evidence Confirms Effectiveness and Patient ...
Apr 19, 2024 · AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive …
Teva Pharmaceutical Industries Ltd. - Teva’s New Real-World Evidence ...
Apr 16, 2024 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …
Study Explores Tardive Dyskinesia Outcomes With Deutetrabenazine Use
Nov 12, 2024 · The survey examined patient-reported ease of use, effectiveness, and satisfaction. In this interim analysis of data from 131 respondents, results revealed that 87% reported satisfaction …
Teva to Present Data for AUSTEDO ® XR ... - Business Wire
Sep 6, 2023 · Presentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-world effectiveness and adherence when initiating treatment with a 4-Week Patient …